AzTrials
AzTrials

Diabetic Macular EdemaPhase 3RESPONDNCT01135914

Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)

A Phase 3 study testing ranibizumab and Laser in people with Diabetic Macular Edema, run by Novartis Pharmaceuticals at 20 sites in Canada.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in comparison with the current standard of care (laser photocoagulation monotherapy), in… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Diabetic Macular Edema
What is being tested?
ranibizumab and Laser
Could I receive a placebo?
No, everyone receives an active treatment
How many people
241 participants
Where
20 sitesCanada
Study dates
Jul 2010to Mar 2013
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Stable Type 1 or Type 2 diabetes mellitus
  • Visual impairment due to focal or diffuse DME in at least one eye

Who cannot join

  • Active conditions in the study eye that could prevent the improvement of visual acuity on study treatment
  • Active eye infection or inflammation
  • History of stroke, renal failure or uncontrolled hypertension
  • Other protocol-defined inclusion/exclusion criteria may apply

Trial locations and contacts

20 sites in 1 country.

20 sites in 1 country

Canada20 sites
  • Calgary Retina Consultants

    Calgary, Alberta

  • Clinique ChirurgiVision

    Drummondville, Quebec

  • Victoria General Hospital, Department of Ophthalmology

    Halifax, Nova Scotia

  • Ivey Eye Institute

    London, Ontario

  • Canadian Centre for Advanced Eye Therapeutics

    Mississauga, Ontario

  • Hôpital Maisonneuve-Rosemont

    Montreal, Quebec

  • Hôpital Notre Dame (CHUM)

    Montreal, Quebec

  • Royal Victoria Hospital

    Montreal, Quebec

  • The Ottawa Hospital - General Campus

    Ottawa, Ontario

  • Centre Oculaire de Québec

    Québec, Quebec

  • Institut de l'oeil des Laurentides

    Québec

  • Saskatoon City Hospital / Spadina Clinic

    Saskatoon, Saskatchewan

  • Dr.Michel Giunta Clinique Médicale

    Sherbrooke, Quebec

  • Memorial University Health Sciences Centre / Bense Eye Centre

    St. John's, Newfoundland and Labrador

  • Memorial University Health Sciences Centre / Newfoundland Drive Medical Clinic

    St. John's

  • St-Michael's Hospital - Dept of Ophthalmology

    Toronto, Ontario

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario

  • Toronto Western Hospital

    Toronto, Ontario

  • UBC - Eye Care Center

    Vancouver, British Columbia

  • Retina Consultants of Victoria

    Victoria, British Columbia

Other trials in Canada

About this study

Official title: A Canadian 12-month, Prospective, Randomized, Open-label, Multicenter, Laser-controlled Phase IIIb Study Assessing the Efficacy, Safety and Cost-efficacy of Ranibizumab as Combination and Monotherapy in Patients With Visual Impairment Due to Diabetic Macular Edema.

To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in comparison with the current standard of care (laser photocoagulation monotherapy), in patients with visual impairment due to DME.

Being tested
ranibizumab, Laser
Keywords
DME, visual impairment, diabetes, macular edema, diabetic macular edema, ranibizumab, laser, photocoagulation, retinopathy, retina
Medical subject headings
Vision Disorders, Diabetes Mellitus, Macular Edema, Retinal Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ranibizumabDrug

    Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.

  • LaserProcedure or surgery

    Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.

Study groups in NCT01135914
Study groupRoleWhat they receive
Combination TherapyExperimentalParticipants received ranibizumab intravitreal injection and laser photocoagulation treatments
Receives: Drug: ranibizumab; Procedure: Laser
Ranibizumab MonotherapyExperimentalParticipants received ranibizumab intravitreal injection therapy only
Receives: Drug: ranibizumab
Laser MonotherapyActive comparatorParticipants received Laser photocoagulation therapy only
Receives: Procedure: Laser

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

    Measured: Baseline and 12 months

Secondary outcomes (7)
  1. Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) at Months 3,6 and 9

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS)is 0 to 100 letters. A positive change from baseline of BCVA indicates improvement.

    Measured: Baseline, 3, 6 and 9 months

  2. Change From Baseline in Central Retinal Thickness (CRT) at Months 3,6,9 and 12

    OCT is a diagnostic imaging technique using low-coherence interferometry to produce cross-sectional tomograms of the posterior segment eye structures. OCT was performed prior to study treatment to assess CRT, presence of fluid in the macula (intra-retinal cyst or fluid) and evaluation of image to monitor disease progression/treatment effect and to determine the need to stop/re-initiate ranibizumab treatment

    Measured: Baseline, 3, 6, 9 and 12 months

  3. Percentage of Patients Achieving a Gain of 15-letters or More (3-lines) in BCVA From Baseline

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A higher percent of patients achieving a gain of ≥15 letters BCVA indicates a better response.

    Measured: Baseline, 3, 6, 9 and 12 months

  4. Percentage of Patients Achieving Gain of Letters From Baseline in BCVA

    Best-Corrected Visual Acuity (BCVA) letters was measured using Early Treatment Diabetic Retinopathy Study (EDTRS)-like chart while participants were in a sitting position at a testing distance of 4 meters. The range of BCVA (EDTRS) is 0 to 100 letters. A gain of 5,10,15 or more BCVA letters from baseline indicates improvement.

    Measured: 12 months

  5. National Eye Institute Visual Functioning Questionnaire - 25 (VFQ-25) Composite Score at Month 12

    The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure the influence of visual disability and visual symptoms on general health domains. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. For each question, the patient was asked to rate their condition on a scale of 1-5 or 1-6, where a low number reflects a better outcome. A composite score for a patient is calculated by aggregating and averaging the scores from the 11 sub-scales (excluding general health sub-scale), and an algorithm is apply to give equal weight to each sub-scale. Sub-scales and composite scores are calculated by converting the response from questionnaires into a 0-100 scale, with 0 as the worst possible outcome and 100 as the best. Missing data was not imputed

    Measured: 12 month

  6. EuroQoL (EQ-5D) Utility Score at Month 12

    The Euro Quality of Life Questionnaire (EQ-5D) standardized instrument was utilized to measure health outcomes related to 5 dimensions, namely: mobility, self-care, usual activities, pain-discomfort, and anxiety/depression. The possible range for each dimension was 1 to 3, where 1="no problems", 2="some problems" and 3="extreme problems". Missing values were not imputed. Using the scoring algorithm derived from the Canadian value sets (Bansback et al., 2012), a utility score for a patient was calculated based on the EQ-5D responses for a given time-point at which the questionnaire was presented to the patient. This mean EQ-5D utility score ranged between 0 (worst health) to 1 (perfect health).

    Measured: 12 month

  7. Time Trade-Off Questionnaire - 25 (TTO) Composite Score at Month 12

    (TTO) questionnaire was used to help determine the patients' health utility. Reported health utility represents the patients' quality of life at the current health state, and is a cardinal value that ranges from 0 (worst possible health or death) to 1 (best possible health). In this questionnaire, patients were first asked to estimate their remaining life expectancy. Second, the patients were presented with a hypothetical situation where a technology existed that could permanently return their vision to normal. This technology would always work, but would decrease their length of survival. Patients were then asked how much of their remaining life expectancy, if any, they would be willing to trade in return for use of the technology and thus for normal vision. The principle of this measure is that if patients were content with their current vision status (i.e., have a utility value of 1.0), they would not want to trade any of their remaining life years to improve their vision.

    Measured: 12 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jun 2010 (estimated)
  2. Study startJul 2010
  3. Primary completionMar 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
241 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01135914
Sponsor's protocol ID
CRFB002DCA05
Acronym
RESPOND
Status last verified
Oct 2014
First submitted
31 May 2010
Last updated
23 Oct 2014

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing ranibizumab and Laser in people with Diabetic Macular Edema, run by Novartis Pharmaceuticals at 20 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 23 Oct 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 20 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 23 Oct 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Mean Change From Baseline in Best Corrected Visual Acuity- (BCVA) at Month 12 (time frame: Baseline and 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Oct 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in